4
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Abnormal Sodium is a Predictor for Respiratory Failure and Mortality in Hospitalized Patients With COVID-19

      abstract
      , MD, PhD, MSc (Hons), MRCP (UK) 1 , , BM,BSC,MRCP 2 , , MSc 3 , , MBChB, MRCP 4 , , MBBS, MRCP 2 , , BSc (Hons) 2 , , MBBS, BSc 2 , , MBBS 2 , , MBBS, BSc 2 , , MBBS, BSc 2 , , MBBS, MRCP 2 , , MBBS, BSc 2 , , MBBS, BSc 2 , , MRCP (UK) 4 , , MD, MRCP 4 , , MBBS, MRCP (UK) 4 , , BSC,MD,FRCP 5 , , MBBS, BSc, FRCP, MD 1 , , MD FRCP 1
      Journal of the Endocrine Society
      Oxford University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Hypernatremia and hyponatremia (serum sodium > 145 mmol/L and < 135 mmol/L, respectively) are independent risk factors for excess mortality in patients with bacterial pneumonia. We sought, for the first time, an association of sodium [Na] abnormalities with mortality, need for advanced respiratory support and Acute Kidney Injury (AKI) in hospitalized patients with coronavirus disease 19 (COVID-19). Methods: This retrospective, longitudinal, cohort study included 488 adults, 277 males and 211 females, with a median age of 68 years, who were hospitalized with COVID-19 to two hospitals in London over an 8-week period (February to May 2020). Results: The in-hospital mortality rate was 31.1% with a medial length of stay of 8 days. High [Na] levels at any timepoint during hospital stay were associated with significantly increased mortality rate (56.6% vs 21.1% in patients who remained constantly normonatremic; odds ratio 3.05, 95% CI 1.69-5.49; p<0.0001). On day 3 and on day 6, high [Na] values predicted mortality with an estimated odds ratio of 2.34 (95% CI 1.08 – 5.05, p=0.0014) and 2.40 (95% CI 1.18 - 4.85, p=0.001), respectively. Non-survivors had a significantly higher 5-day rise in serum [Na] when compared to survivors (3.60 mmol/L vs 1.14 mmol/L respectively, p<0.05). Patients with low serum [Na] levels on admission had a 2.18-fold increase (95% CI 1.34-3.46, p=0.001) in the likelihood of needing advanced ventilatory support compared to those with normal [Na] (31.7% vs 17.5%, respectively). However, exposure to hyponatremia at any timepoint, including at presentation or on day 3 or day 5, was not associated with excess risk of

          death. AKI affected 37.1% of patients (21.3%, 7.4% and 8.4% stages 1, 2 and 3 respectively) but was not related to serum sodium values. Conclusions: In hospitalized COVD-19 patients, hypernatremia at any timepoint was associated with excess mortality, suggesting that [Na] concentration may facilitate risk stratification. In addition, whilst our data cannot prove causality, these findings highlight the significance of judicious rehydration in such patients.

          Related collections

          Author and article information

          Journal
          J Endocr Soc
          J Endocr Soc
          jes
          Journal of the Endocrine Society
          Oxford University Press (US )
          2472-1972
          Apr-May 2021
          03 May 2021
          : 5
          : Suppl 1 , ENDO 2021 Abstracts Annual Meeting of the Endocrine Society
          : A622-A623
          Affiliations
          [1 ] University College London , London, United Kingdom
          [2 ] Whittington Hospital , London, United Kingdom
          [3 ] Imperial College London , London, United Kingdom
          [4 ] University College London Hospital , London, United Kingdom
          [5 ] Royal Free Hospital , London, United Kingdom
          Article
          bvab048.1269
          10.1210/jendso/bvab048.1269
          8135456
          13738280-2d62-45ac-a480-cfc48390ee26
          © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

          History
          Page count
          Pages: 2
          Categories
          Neuroendocrinology and Pituitary
          Neuroendocrinology and Pituitary Clinical Advances
          AcademicSubjects/MED00250

          Comments

          Comment on this article